Spinogenix's latest research showcases Tazbentetol's capacity to mitigate diabetic retinal neuropathy, highlighting its significance in vision preservation.

Spinogenix announced interim results from its Phase 2 trial evaluating tazbentetol, a first-in-class investigational synaptic regenerative therapy for schizophrenia. The study showed early improvement

Extended follow-up and new AAIC 2026 data show that tazbentetol, a first-in-class oral synaptic regenerative therapy, produced rapid and durable improvement in cognition and EEG biomarkers in patients with mild-to-moderate Alzheimer disease.

Tazbentetol, a First-in-Class, Oral Synaptic Regenerative Investigational Therapy, Demonstrated Favorable Safety Profile and Durable Therapeutic Benefits Clinical Case Study Presented at AAIC Highlights Caregiver Report of Rapid Cognitive Improvement with Supporting Clinical Outcome...

Latest data reveals Spinogenix's Tazbentetol shows impressive long-term cognitive benefits for Alzheimer's patients after extended treatment.

If approved, Spinogenix's tazbentetol could become the first therapy to target synaptic degradation in Alzheimer's disease.

Spinogenix has received a Fast Track Designation from the FDA for Tazbentetol, a pioneering treatment for ALS that shows promise in restoring synapse function.

Spinogenix is set to showcase groundbreaking preclinical research at ARVO 2026, demonstrating Tazbentetol's neuroprotective abilities in glaucoma and diabetic retinopathy models.

Spinogenix's Phase 2 trial data reveals early improvements in treating schizophrenia with Tazbentetol, highlighting safety and symptom reduction.

Spinogenix has successfully concluded patient enrollment for its Phase 2 trial of Tazbentetol, a novel treatment for schizophrenia, aiming to improve cognitive and negative symptoms.

Spinogenix's Phase 2a trial reveals Tazbentetol's potential in improving cognitive function in Alzheimer's patients, showing notable safety and efficacy.

Spinogenix, Inc. has announced that the WHO approved 'tazbentetol' as the non-proprietary name for its innovative therapy aimed at neurodegenerative conditions.

Designation Enables an Enhanced Development Path for Tazbentetol and Underscores the Unmet Need for New Treatments In ALS Milestone Follows Recent Announcement of Phase 2a Results Showing Preliminary Evidence that Tazbentetol's First in Class Synaptic Regenerative Mechanism Slowed Rate of...

New Preclinical Data Show Tazbentetol Reduces Retinal Cell Loss and Preserves Visual Function in Glaucoma and Diabetic Retinopathy Models LOS ANGELES, May 3, 2026 /PRNewswire/ -- Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics designed...

First-in-Class Synaptic Regenerative Therapy Demonstrates Favorable Safety Profile and Early Potential to Improve Symptoms of Schizophrenia LOS ANGELES, March 26, 2026 /PRNewswire/ -- Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics that...

First-in-Class Synaptic Regenerative Therapy Aims to Address Positive, Negative and Cognitive Symptom Domains Oral Presentation on Interim Data Planned for Schizophrenia International Research Society (SIRS) Annual Congress LOS ANGELES, March 11, 2026 /PRNewswire/ -- Spinogenix, Inc., a...

Tazbentetol, a Potential First-in-Class, Oral Synaptic Regenerative Investigational Therapy, Showed a Favorable Safety Profile and Promising Benefits in Multiple Outcome Measures Subset Exhibited Significant Improvement in AD-Related Brain Activity, As Assessed by EEG LOS ANGELES, Dec. 8,...

Tazbentetol is a First-in-Class, Synaptic Regenerative Investigation Therapy for Alzheimer's disease, ALS, Schizophrenia and Glaucoma LOS ANGELES, Dec. 1, 2025 /PRNewswire/ -- Spinogenix, Inc., a clinical-stage pharmaceutical company pioneering first-in-class therapeutics that restore...

Experimental therapy targets neural repair to combat blindness from glaucoma and diabetic retinopathy LOS ANGELES — Spinogenix is spotlighting new preclinical findings that could reshape how vision-threatening diseases are treated, as its experimental drug tazbentetol (SPG302) demonstrates the ability to protect and restore retinal function. The results are being presented at the Association for Research …

Tazbentetol is an investigational, once-daily synaptic regenerative therapy designed to restore cognitive and motor function in ALS.